Exact Sciences Corp - EXAS STOCK NEWS

Katie Couric has partnered with Exact Sciences (NASDAQ: EXAS) to launch a year-long campaign called 'Mission to Screen,' aiming to raise awareness about colon cancer screening. The initiative emphasizes the importance of screening for all adults aged 45 and older, especially given the rising incidence of colon cancer in younger individuals. Cologuard, Exact Sciences' FDA-approved noninvasive test, is highlighted as a key screening option. Over 44 million Americans aged 45-plus remain unscreened, despite the critical role of early detection in improving treatment outcomes.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in two upcoming investor conferences. The Cowen Health Care Conference will feature a fireside chat on March 7, 2022 at 9:50 a.m. ET, while the Raymond James Institutional Investors Conference will hold a fireside chat on March 8, 2022 at 4:00 p.m. ET. Webcasts can be accessed via the investor relations section of Exact Sciences' website.

Exact Sciences focuses on advanced cancer diagnostics, including Cologuard and Oncotype tests.

Exact Sciences Corp. (Nasdaq: EXAS) reported $473.8 million in revenue for Q4 2021, a 2% increase year-over-year, while total revenue for 2021 reached $1,767.1 million. Screening revenue grew 11% to $277.7 million, and Precision Oncology revenue rose 27% to $149.0 million. However, COVID-19 testing revenue fell 52% to $47.1 million. The net loss for Q4 was $220.6 million or $1.28 per share, improving from a loss of $418.3 million in the same quarter the previous year. For 2022, the company projects revenue between $1,975 and $2,027 million.

Exact Sciences Corp. (Nasdaq: EXAS) announced plans to release its fourth quarter 2021 financial results on February 22, 2022, after U.S. market close. This will be followed by a webcast and conference call at 5 p.m. ET to discuss the results and business developments. The company, known for its cancer diagnostic tests, continues to expand its product pipeline with a focus on addressing critical cancer challenges. Investors can access the webcast live on the company's website.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in upcoming virtual conferences. Notable events include the SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET, and the Citi Healthcare Conference on February 23, 2022, at 2:45 p.m. ET. Investors can join the webcasts via the investor relations section on Exact Sciences' website. Exact Sciences is dedicated to developing cancer screening and diagnostic tests, including the well-known Cologuard and Oncotype DX.

Exact Sciences Corp. (NASDAQ: EXAS) reported promising data for its second-generation Cologuard test, achieving an overall sensitivity of 95.2% for colorectal cancer with a specificity of 92.4%. The test demonstrated 83.3% sensitivity for high-grade dysplasia and 57.2% for advanced precancerous lesions. The findings will be presented at ASCO GI on January 22. If successful, the new Cologuard could enhance screening rates and reduce unnecessary follow-up colonoscopies. A pivotal trial is ongoing, with results expected late 2022 or early 2023.

Exact Sciences Corp. (NASDAQ: EXAS) has acquired PreventionGenetics, a genetic testing laboratory, for $190 million to enhance its cancer diagnostics portfolio and expand into hereditary cancer testing (HCT). The acquisition aims to leverage PreventionGenetics' expertise and technology to improve patient access to HCT, helping individuals understand their cancer risks. With expected 2021 revenue of $36 million, the acquisition strengthens Exact Sciences' presence in the genetics realm, tapping into a network of nearly 300,000 healthcare providers.

Exact Sciences Corp. (Nasdaq: EXAS) announced estimated fourth quarter 2021 revenue between $472 million and $475 million, reflecting a 2% increase year-over-year. Excluding COVID-19 testing, revenue grew 16%. Screening revenue is projected at $277 million to $278 million (up 11%), while Precision Oncology revenue is estimated at $148.5 million to $149.5 million (up 27%). However, COVID-19 testing revenue fell by 53%. The company aims for strong growth in cancer detection services.

Exact Sciences Corp. (NASDAQ: EXAS) has entered an exclusive licensing agreement with OncXerna Therapeutics to offer the innovative Xerna TME Panel lab services to U.S. patients. This tumor microenvironment panel aids in predicting patient responses to immunotherapies, enhancing therapy selection for oncologists. The integration with Exact Sciences’ GEM ExTra test promises to improve patient outcomes by providing deeper insights into treatment efficacy. The Xerna TME Panel remains investigational and has not yet received FDA approval.